Myriad Genetics to Present Seven Studies at the 2019 National Society of Genetic Counselors Annual Meeting October 28, 2019 Myriad Genetics to Present Seven Studies at the 2019 National Society of Genetic Counselors Annual Meeting SALT LAKE CITY, Oct. 28, 2019 (GLOBE NEWSWIRE) -- Myr... Continue Reading
Myriad Applauds the U.S. Preventive Services Task Force Recommendation on BRCA-Related Cancer Prevention August 22, 2019 Myriad Applauds the U.S. Preventive Services Task Force Recommendation on BRCA-Related Cancer Prevention More Women May Benefit from Hereditary Cancer Risk Ass... Continue Reading
Prolaris® Test Accurately Predicts Risk of Metastasis in Men Diagnosed with Localized Prostate Cancer June 27, 2019 Prolaris® Test Accurately Predicts Risk of Metastasis in Men Diagnosed with Localized Prostate Cancer Validation Study Shows Prolaris Test Identifies Men Who M... Continue Reading
BRACAnalysis CDx® Approved by U.S. Food and Drug Administration as Companion Diagnostic for AstraZeneca’s Lynparza® (olaparib) in Patients with Advanced-Stage, BRCA-Mutated Ovarian Cancer June 24, 2019 BRACAnalysis CDx® Approved by U.S. Food and Drug Administration as Companion Diagnostic for AstraZeneca’s Lynparza® (olaparib) in Patients with Advanced-Sta... Continue Reading
Myriad Genetics Announces New Results from Two Large Studies of Its myRisk® Hereditary Cancer Test at American Society of Clinical Oncology June 3, 2019 Myriad Genetics Announces New Results from Two Large Studies of Its myRisk® Hereditary Cancer Test at American Society of Clinical Oncology SALT LAKE CITY, Jun... Continue Reading
EndoPredict® Predicts the Chemotherapy Benefit in Women with Early ER-positive, HER2-negative Breast Cancer April 30, 2019 [vc_row][vc_column][vc_column_text el_class=" text-corporate"] EndoPredict® Predicts the Chemotherapy Benefit in Women with Early ER-positive, HER2-negative Br... Continue Reading
BRACAnalysis CDx® Approved by U.S. Food and Drug Administration as Companion Diagnostic for AstraZeneca’s Lynparza® (olaparib) in Patients with Advanced-Stage, BRCA-Mutated Ovarian Cancer December 19, 2018 BRACAnalysis CDx® Approved by U.S. Food and Drug Administration as Companion Diagnostic for AstraZeneca’s Lynparza® (olaparib) in Patients with Advanced-Sta... Continue Reading
EndoPredict® Test Receives Positive NICE Recommendation for Patients with Early Breast Cancer December 19, 2018 EndoPredict® Test Receives Positive NICE Recommendation for Patients with Early Breast Cancer NICE Decision is a Major Milestone in Expanding Access to Patient... Continue Reading
Prospective Study Demonstrates EndoPredict® Can Guide Chemotherapy Decision For Women with Early-Stage Breast Cancer December 7, 2018 Prospective Study Demonstrates EndoPredict® Can Guide Chemotherapy Decision For Women with Early-Stage Breast Cancer SALT LAKE CITY, Dec. 07, 2018 (GLOBE NEWS... Continue Reading
Myriad Announces Important New Data for Its EndoPredict® Breast Cancer Test Will Be Presented at the 2018 San Antonio Breast Cancer Symposium December 7, 2018 EndoPredict is the Only Test to Answer Three Critical Questions: Risk of Breast Cancer Recurrence, Benefits of Chemotherapy and Who Can Forgo Extended Endocrine... Continue Reading